reports
- Patrik Ling
- Patrik Ling
SynAct Pharma (No_rec, TP: SEK) - Irregularities in the RESOLVE trial
SynAct Pharma was expected to release data from the 4-week RESOLVE trial in early November. Instead, the company announced it has found multiple irregularities in the data and has therefore initiated a third-party audit of both the RESOLVE and EXPAND trials (as several sites are the same and the same CRO has run the trials). Data should now be released in early 2024 instead. This news has further increased the risk and introduced more uncertainty about the result of the post-hoc analysis from th...
- Patrik Ling
SynAct Pharma (Hold, TP: SEK15.00) - EXPAND trial failed
SynAct Pharma presented disappointing data today (4 September), stating that the EXPAND trial failed to reach a difference between the active arm and placebo. Although the placebo effect might have been greater than expected, the proportion of patients in the active arm that reached ACR20 was also lower than expected. We believe this puts a lot of pressure on the company, as the financial situation is stretched and new capital likely needs to be raised in H2. We have downgraded to HOLD (BUY) and...
- Alexander Aukner
- Christoffer Wang Bjørnsen
- Martin Huseby Karlsen
- Nicolas McBeath
- Ole-Andreas Krohn
- Patrik Ling
- Helene Kvilhaug Brøndbo
- Jacob Berg Nielsen
- Ola Trovatn
- Ole-Andreas Krohn
- Patrik Ling
- Patrik Ling
SynAct Pharma - Initiation of coverage - Many moving parts
SynAct Pharma is a development-stage biotech company focusing on rheumatoid arthritis (RA), with scope for potential indications in other inflammatory diseases. We believe two positive data readouts in September/October could pave the way for a large out-licensing deal. We initiate coverage with a BUY and SEK170 target price.
- Erik Cassel
PHO PHOTOCURE ASA
DEMANT DEMANT A/S
OSSR OSSUR HF.
NOVO B NOVO NORDISK A/S CLASS B
SOBI SWEDISH ORPHAN BIOVITRUM AB
GN GN STORE NORD A/S
ALK B ALK-ABELLO A/S CLASS B
CRAD B C-RAD AB
HNSA HANSA BIOPHARMA AB
EGTX EGETIS THERAPEUTICS AB
VICO VICORE PHARMA HOLDING AB
EKTA B ELEKTA AB CLASS B
COLO B COLOPLAST A/S CLASS B
HUM HUMANA AB
ATT ATTENDO
AZN ASTRAZENECA PLC
ONCO ONCOPEPTIDES AB
BONEX BONESUPPORT HOLDING AB
ARJO B ARJO B
AMBU B AMBU A/S CLASS B
VITR VITROLIFE AB
MCAP MEDCAP
ULTI ULTIMOVACS
BOUL BOULE DIAGNOSTICS AB
IVACC INTERVACC AB
QLINEA Q LINEA AB
OSSD OSSDSIGN
VACC VACCIBODY AS
SYNACT SYNACT PHARMA
ABS ARCTIC BIOSCIENCE
NANEXA NANEXA AB
LINV LINC
IRLAB A IRLAB THERAPEUTICS
FLUO FLUOGUIDE AS
VIMIAN VIMIAN GROUP AB
LUND B H. LUNDBECK A/S
- Adam Karlsson
- Adam Karlsson
SOBI SWEDISH ORPHAN BIOVITRUM AB
HNSA HANSA BIOPHARMA AB
EGTX EGETIS THERAPEUTICS AB
NANO NORDIC NANOVECTOR ASA
AZN ASTRAZENECA PLC
ONCO ONCOPEPTIDES AB
ULTI ULTIMOVACS
IVACC INTERVACC AB
VACC VACCIBODY AS
SYNACT SYNACT PHARMA
ABS ARCTIC BIOSCIENCE
NANEXA NANEXA AB
LINV LINC
IRLAB A IRLAB THERAPEUTICS
FLUO FLUOGUIDE AS
LUND B H. LUNDBECK A/S
- Adam Karlsson
- Adam Karlsson
- Adam Karlsson
- Erik Cassel
- Gonzalo Artiach
- Jakob Lembke
- Morten Larsen
NOVO B NOVO NORDISK A/S CLASS B
SOBI SWEDISH ORPHAN BIOVITRUM AB
CRAD B C-RAD AB
HNSA HANSA BIOPHARMA AB
EGTX EGETIS THERAPEUTICS AB
SANION SANIONA AB
NANO NORDIC NANOVECTOR ASA
HUM HUMANA AB
ATT ATTENDO
AZN ASTRAZENECA PLC
BIOVIC B BIOVICA INTERNATIONAL AB
ONCO ONCOPEPTIDES AB
BONEX BONESUPPORT HOLDING AB
MCAP MEDCAP
PCIB PCI BIOTECH HOLDING ASA
ULTI ULTIMOVACS
BOUL BOULE DIAGNOSTICS AB
IVACC INTERVACC AB
QLINEA Q LINEA AB
VACC VACCIBODY AS
SYNACT SYNACT PHARMA
CLNK B CELLINK AB
ABS ARCTIC BIOSCIENCE
NANEXA NANEXA AB
LINV LINC
IRLAB A IRLAB THERAPEUTICS
FLUO FLUOGUIDE AS
- Adam Karlsson
- Adam Karlsson
- Christer Linde
GIG GAMING INNOVATION GROUP
ELTEL ELTEL AB
ELAN B ELANDERS AB SERIES B
PRIC B PRICER AB B
CAT B TEST
SEMC SEMCON AB
CTT CTT SYSTEMS AB
FSKRS FISKARS OYJ ABP
POOL B POOLIA AB SERIES B
MSON B MIDSONA AB SERIES B
BRE2 BREDBAND2 I SKANDINAVIEN AB
NETI B NET INSIGHT AB SERIES B
DIOS DIOS FASTIGHETER AB
CRAD B C-RAD AB
EAST EASTNINE AB
DIST DISTIT AB
ENZY ENZYMATICA AB
NAPA NAPATECH
ORGANOCLICK AB
SVIK STUDSVIK
SINT SINTERCAST AB
IVSO INVISIO
G5EN G5 ENTERTAINMENT AB
FNOX FORTNOX AB
EOLU B EOLUS VIND AB
ALCA ALCADON GROUP
BIOVIC B BIOVICA INTERNATIONAL AB
BNORDIK BANKNORDIK P/F
FNM FERRONORDIC AB
STRO STRONGPOINT ASA
FLEXM FLEXION MOBILE
LITI LITIUM
BRIXMTF BRIOX
EURO EUROCON CONSULTING AB
OVZON OVZON AB
AWRD AWARDIT AB
QLINEA Q LINEA AB
OSSD OSSDSIGN
FASTAT FASTATOR
PMG PLAY MAGNUS AS
SYNACT SYNACT PHARMA
NANEXA NANEXA AB
GARO GARO AKTIEBOLAG
TETY TETHYS OIL AB
FLUO FLUOGUIDE AS
CARE CAREIUM AB A
PACT PROACT IT GROUP
- Adam Karlsson
- Gonzalo Castanon
- Adam Karlsson
- Adam Karlsson
- Erik Cassel
PHO PHOTOCURE ASA
DEMANT DEMANT A/S
OSSR OSSUR HF.
NOVO B NOVO NORDISK A/S CLASS B
SOBI SWEDISH ORPHAN BIOVITRUM AB
GN GN STORE NORD A/S
LUN H. LUNDBECK A/S
ALK B ALK-ABELLO A/S CLASS B
CRAD B C-RAD AB
HNSA HANSA BIOPHARMA AB
EGTX EGETIS THERAPEUTICS AB
ENZY ENZYMATICA AB
SANION SANIONA AB
NANO NORDIC NANOVECTOR ASA
EKTA B ELEKTA AB CLASS B
COLO B COLOPLAST A/S CLASS B
HUM HUMANA AB
ATT ATTENDO
AZN ASTRAZENECA PLC
BIOVIC B BIOVICA INTERNATIONAL AB
ONCO ONCOPEPTIDES AB
BONEX BONESUPPORT HOLDING AB
ARJO B ARJO B
AMBU B AMBU A/S CLASS B
VITR VITROLIFE AB
MCAP MEDCAP
PCIB PCI BIOTECH HOLDING ASA
ULTI ULTIMOVACS
BOUL BOULE DIAGNOSTICS AB
IVACC INTERVACC AB
QLINEA Q LINEA AB
OSSD OSSDSIGN
VACC VACCIBODY AS
SYNACT SYNACT PHARMA
CLNK B CELLINK AB
ABS ARCTIC BIOSCIENCE
NANEXA NANEXA AB
LINV LINC
FLUO FLUOGUIDE AS
VIMIAN VIMIAN GROUP AB
- Adam Karlsson
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.